Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
To determine if angiotensin-II AT-1 receptor blockade(ARB) may improve insulin sensitivity
assessed by the hyperinsulinaemic isoglycaemic glucose clamp, more than CCB therapy at a
comparable dose with regards to the blood pressure-lowering effect.
Phase:
Phase 4
Details
Lead Sponsor:
Ullevaal University Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Amlodipine Angiotensin II Angiotensinogen Losartan